Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)

Loading history...

Population:

Intervention:

Comparison:

Outcome:

Population:

Intervention:

Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

Low molecular weight heparin effective for prevention of venous thromboembolism in patients with lower-leg immobilisation PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Low molecular weight heparin effective for prevention of venous thromboembolism in patients with lower-leg immobilisation Clinical question How effective is low molecular weight heparin (LMWH) for prevention of venous (...) thromboembolism (VTE) in patients with lower leg immobilisation? Bottom line LMWH significantly reduces VTE when immobilisation of the lower leg is required in outpatients. Further analysis showed a significant reduction in the occurrence of DVT when using LMWH in the following patient subgroups: surgical patients; non-surgical patients; patients with fractures; patients with soft-tissue injuries; patients with below-knee casts; a group with proximal thrombosis and a group with distal thrombosis. LMWH should

Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term (...) treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials Louzada ML, Majeed H, Wells PS CRD summary This review assessed the efficacy of low molecular weight heparin compared to Vitamin K antagonists for long-term treatment of cancer-associated venous thromboembolism in adults and found that low molecular weight heparin was the superior treatment. Based on the evidence, the authors' conclusions and recommendation for further research appeared

Outbreak of Adverse Reactions Associated with Contaminated Heparin. BACKGROUND: In January 2008, the Centers for Disease Control and Prevention began a nationwide investigation of severe adverse reactions that were first detected in a single hemodialysis facility. Preliminary findings suggested that heparin was a possible cause of the reactions. METHODS: Information on clinical manifestations and on exposure was collected for patients who had signs and symptoms that were consistent (...) with an allergic-type reaction after November 1, 2007. Twenty-one dialysis facilities that reported reactions and 23 facilities that reported no reactions were included in a case-control study to identify facility-level risk factors. Unopened heparin vials from facilities that reported reactions were tested for contaminants. RESULTS: A total of 152 adverse reactions associated with heparin were identified in 113 patients from 13 states from November 19, 2007, through January 31, 2008. The use of heparin

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. BACKGROUND: Low-molecular-weight heparins and heparinoids are anticoagulants that may be associated with lower risks of haemorrhage and more powerful antithrombotic effects than standard unfractionated heparin. This is an updated version of the original Cochrane review first published in Issue 1, 1995 and previously updated in Issue 2, 2005. OBJECTIVES: To compare the effects (...) of low-molecular-weight heparins or heparinoids with those of unfractionated heparin in people with acute, confirmed or presumed, ischaemic stroke. SEARCH STRATEGY: We searched the Cochrane Stroke Group Trials Register (last searched June 2007). In addition we searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2007), MEDLINE (1966 to June 2007) and EMBASE (1980 to June 2007). For previous versions of this review we searched MedStrategy (1995) and also contacted pharmaceutical companies

Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease BestBets: Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease Report By: Andrew Munro - Staff Specialist Search checked by Cain English - Emergency Registrar Institution: Coffs Harbour Base Hospital Date (...) Submitted: 4th September 2007 Date Completed: 8th May 2008 Last Modified: 5th November 2007 Status: Green (complete) Three Part Question In [patients with DVT] is [subcutaneous unfractionated heparin as efficacious as low-molecular-weight heparin] in the [prevention of thrombo-embolic sequelae]? Clinical Scenario An Emergency Department Registrar presented a paper at our journal club showing the efficaciousness and cost effectiveness of home treatment with unfractionated heparin (UFH) in comparison

Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System. BACKGROUND: There is an urgent need to determine whether oversulfated chondroitin sulfate (OSCS), a compound contaminating heparin supplies worldwide, is the cause of the severe anaphylactoid reactions that have occurred after intravenous heparin administration in the United States and Germany. METHODS: Heparin procured from the Food and Drug Administration, consisting of suspect lots of heparin (...) associated with the clinical events as well as control lots of heparin, were screened in a blinded fashion both for the presence of OSCS and for any biologic activity that could potentially link the contaminant to the observed clinical adverse events. In vitro assays for the activation of the contact system and the complement cascade were performed. In addition, the ability of OSCS to recapitulate key clinical manifestations in vivo was tested in swine. RESULTS: The OSCS found in contaminated lots

Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. BACKGROUND: Complications associated with peripherally placed percutaneous central venous catheters (PCVC) in neonates include mechanical complications (catheter thrombosis, occlusion or dislodgement) and infection. Strategies to prevent catheter thrombosis and occlusion include the use of heparin. However, heparin is known to be associated (...) with complications such as bleeding and thrombocytopenia. OBJECTIVES: PRIMARY OBJECTIVE: To assess the effectiveness of heparin for prevention of catheter related thrombosis. SECONDARY OBJECTIVES: To assess the effectiveness of heparin on catheter occlusion, duration of catheter patency, catheter related sepsis and complications associated with the use of heparin. SEARCH STRATEGY: A literature search of MEDLINE, EMBASE, CINAHL from their inception to December 2007, The Cochrane Library (Issue 4, 2007

Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. BACKGROUND: There are a limited number of treatment options for patients with ulcerative colitis (UC). An increased risk of thrombosis in UC coupled with an observation that UC patients being treated with anticoagulant therapy for thrombotic events had an improvement in their bowel symptoms led to trials examining the use of unfractionated heparin (UFH) and low molecular weight heparins (LMWH) in (...) patients with active UC. OBJECTIVES: To review randomized trials examining the efficacy of unfractionated heparin (UFH) or low molecular weight heparins (LMWH) for remission induction in patients with ulcerative colitis. SEARCH STRATEGY: The MEDLINE (PUBMED), and EMBASE databases, The Cochrane Central Register of Controlled Trials, the Cochrane IBD/FBD group specialized trials register, review papers on ulcerative colitis, and references from identified papers were searched in an effort to identify all

Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Bramham K, Varrier M, Asgari E, Makanjuola D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the costs and outcomes associated with the use of unfractionated heparin (UFH) and a low-molecular-weight heparin (LMWH, Tinzaparin TM ) for anticoagulation in patients on haemodialysis. The authors concluded